Baseline cognitive function predicts full remission of suicidal symptoms among patients with treatment-resistant depression and strong suicidal ideation after low-dose ketamine infusion.
Wei-Chen Lin, Tung-Ping Su, Cheng-Ta Li, Hui-Ju Wu, Shih-Jen Tsai, Ya-Mei Bai, Pei-Chi Tu, Mu-Hong Chen
Journal of Psychopharmacology August 2023 DOI: 10.1177/02698811231182107 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 65 |
| Population | Patients with treatment-resistant depression and strong suicidal ideation |
| Intervention | Ketamine |
| Dose | 0.5 mg/kg |
| Duration | Assessments at baseline and postinfusion Days 2, 3, 5, and 7; antisuicidal effect persisted for 1 week |
| Topics | Ketamine Depression Esketamine |
| Keywords | Antisuicidal effect Response inhibition Working memory |
| Key findings | A single 0.5 mg/kg ketamine infusion produced full remission of suicidal symptoms lasting 3 days and an antisuicidal effect lasting 1 week. Lower baseline cognitive impairment, indicated by a higher rate of correct responses on a working memory task, was associated with a rapid and sustained antisuicidal effect. |
Abstract
Whether pretreatment working memory and response inhibition function are associated with the rapid and sustained antisuicidal effect of low-dose ketamine among patients with treatment-resistant depression (TRD) and strong suicidal ideation is unclear. We enrolled 65 patients with TRD, comprising 33 who received a single infusion of 0.5 mg/kg ketamine and 32 who received a placebo infusion. The participants performed working memory and go/no-go tasks prior to infusion. We assessed suicidal symptoms at baseline and on postinfusion Days 2, 3, 5, and 7. The full remission of suicidal symptoms persisted for 3 days after a single ketamine infusion and the ketamine-related antisuicidal effect persisted for 1 week. Lower cognitive impairment at baseline (indicated by a higher rate of correct responses on a working memory task) was associated with the rapid and sustained antisuicidal effect of low-dose ketamine in patients with TRD and strong suicidal ideation. Patients with TRD and strong suicidal ideation but low cognitive impairment may benefit the most from the antisuicidal effect of low-dose ketamine.
Comparable studies
Other randomized controlled trials on ketamine for depression, most cited first.
Citations in the library
Cited by 3
- Clinical trials since 2020 of rapid anti-suicidal ideation effects of ketamine and its enantiomers: a systematic review. Translational Psychiatry February 6, 2025
- The use of repetitive transcranial magnetic stimulation (rTMS), electroconvulsive therapy (ECT), ketamine, and esketamine in reducing suicidality in major depressive disorder: A comprehensive narrative review Psychiatry Research February 19, 2026
- Ketamine: A new chapter for clinical psychopharmacology? Journal of Psychopharmacology August 1, 2023
Cites 13
- The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis American Journal of Psychiatry October 3, 2017
- EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT-RESISTANT DEPRESSION Depression and Anxiety March 25, 2014
- Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials Australian & New Zealand Journal of Psychiatry November 15, 2019
- The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. Journal of Affective Disorders November 1, 2020
- The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. Journal of Psychiatric Research December 11, 2020
and 8 more in the library